450 related articles for article (PubMed ID: 36974474)
1. Approach to the Patient With Prolactinoma.
Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
[TBL] [Abstract][Full Text] [Related]
2. [Prolactinoma].
Glezer A; Bronstein MD
Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
[TBL] [Abstract][Full Text] [Related]
3. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
4. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD
Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
6. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of prolactinomas.
Webster J
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):395-408. PubMed ID: 10909431
[TBL] [Abstract][Full Text] [Related]
8. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
10. Update on prolactinomas. Part 2: Treatment and management strategies.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
[TBL] [Abstract][Full Text] [Related]
11. Prolactinomas.
Wildemberg LE; Fialho C; Gadelha MR
Presse Med; 2021 Dec; 50(4):104080. PubMed ID: 34687915
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
13. Contemporary management of prolactinomas.
Liu JK; Couldwell WT
Neurosurg Focus; 2004 Apr; 16(4):E2. PubMed ID: 15191331
[TBL] [Abstract][Full Text] [Related]
14. Prolactinomas.
Glezer A; Bronstein MD
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
[TBL] [Abstract][Full Text] [Related]
15. [Prolactinoma treatment status in the cabergoline era].
Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
[TBL] [Abstract][Full Text] [Related]
16. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
17. GIANT PROLACTINOMA. A CASE REPORT.
Šulavíková Z; Krásnik V
Cesk Slov Oftalmol; 2023; 79(3):143-148. PubMed ID: 37344216
[TBL] [Abstract][Full Text] [Related]
18. Management of prolactinomas in Brazil: an electronic survey.
Vilar L; Naves LA; Casulari LA; Azevedo MF; Albuquerque JL; Serfaty FM; Pinho Barbosa FR; de Oliveira AR; Montenegro RM; Montenegro RM; Ramos AJ; Dos Santos Faria M; Musolino NR; Gadelha MR; Boguszewski CL; Bronstein MD
Pituitary; 2010 Sep; 13(3):199-206. PubMed ID: 20107911
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
20. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]